Crispr Theraptc (NASDAQ:CRSP) insider Tyler Dylan-Hyde sold 15,000 shares of the business’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $18.57, for a total transaction of $278,550.00. Following the sale, the insider now directly owns 167,727 shares of the company’s stock, valued at approximately $3,114,690.39. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Crispr Theraptc (CRSP) opened at 18.34 on Friday. The company’s market cap is $744.44 million. Crispr Theraptc has a one year low of $11.63 and a one year high of $25.00. The company has a 50-day moving average of $17.38 and a 200 day moving average of $17.51.
Crispr Theraptc (NASDAQ:CRSP) last released its quarterly earnings results on Thursday, August 10th. The company reported ($0.56) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.06. The company had revenue of $3.60 million for the quarter, compared to analyst estimates of $3.29 million. Crispr Theraptc had a negative net margin of 406.61% and a negative return on equity of 47.46%. The company’s quarterly revenue was up 350.0% on a year-over-year basis. Analysts anticipate that Crispr Theraptc will post ($2.43) earnings per share for the current year.
A number of equities research analysts have recently issued reports on the stock. Cann assumed coverage on shares of Crispr Theraptc in a research report on Monday, July 17th. They set a “market perform” rating for the company. Chardan Capital reissued a “buy” rating on shares of Crispr Theraptc in a research report on Monday, August 14th. SunTrust Banks, Inc. initiated coverage on shares of Crispr Theraptc in a research report on Thursday, July 13th. They set a “hold” rating and a $16.00 price objective for the company. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a report on Tuesday, July 18th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $21.92.
Crispr Theraptc Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
What are top analysts saying about Crispr Theraptc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Crispr Theraptc and related companies.